Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast CancerSaji S.a · Toi M.d · Morita S.e · Iwata H.f · Ito Y.b · Ohno S.g · Kobayashi T.c · Hozumi Y.h · Sakamoto J.i
aDepartment of Surgery and Breast Oncology, Division of Clinical Trials and Research, Tokyo Metropolitan Komagome Hospital, bClinical Chemotherapy, Cancer Institute Hospital and cDepartment of Hematology and Oncology, Jikei University School of Medicine, Tokyo, dDepartment of Surgery, Graduate School of Medicine and eDepartment of Epidemiology and Health Care Research, School of Public Health, Kyoto University, Kyoto, fDepartment of Breast Oncology, Aichi Cancer Center Hospital, Aichi, gDepartment of Breast Oncology, National Kyushu Cancer Center, Fukuoka, hDepartment of Surgery, Jichi Medical School, Tochigi, and iMedical Administration Course of Masters Degree Program, Nagoya University, Nagoya, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: The present study aimed to identify the recommended dose (RD) of capecitabine, epirubicin and cyclophosphamide (CEX) combination treatment for inoperable or metastatic breast cancer and to assess response rate, tolerability and pharmacokinetics in Japanese patients. Methods: Patients received 3-week cycles of fixed-dose intravenous cyclophosphamide (600 mg/m2, day 1), intravenous epirubicin (75–100 mg/m2, day 1) and oral capecitabine (628–900 mg/m2 twice daily, days 1–14). Dose escalation/deescalation decisions for consecutive cohorts were made using the continual reassessment method (CRM). RD was defined as dose level closest to that causing dose-limiting toxicity (DLT) in 33% of patients. Results: Among the 17 patients enrolled, 3 experienced DLT (hand-foot syndrome, anorexia, mucositis; all grade 3) and 3 (18%) febrile neutropenia. Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8–42%), 35% (17–56%) and 56% (38–71%), respectively. Level 3 was thus chosen as the RD. Combination treatment did not affect pharmacokinetic parameters of capecitabine, epirubicin or their metabolites. Objective responses were achieved by 7 patients (41%), including partial responses in 4 of 6 patients (67%) receiving the RD. Conclusion: CEX represents a well-tolerated regimen, and RD for Japanese patients was determined to be capecitabine 900 mg/m2 twice daily in combination with epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 using the CRM.
© 2008 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.